Subsequent Events

6 Months Ended

Jun. 30, 2019

Subsequent Events

Subsequent Events

16. Subsequent Events

Linda Rosi v. Aclaris Therapeutics, Inc. et al. On July 30, 2019, plaintiff Linda Rosi (the “Plaintiff”) filed a purported class action complaint in the U.S. District Court for the Southern District of New York against the Company and certain of its executive officers (the “Defendants”), alleging violations by the Defendants of certain federal securities laws. Plaintiff alleges that the Defendants made misleading statements to investors about the Company’s business, operations and prospects and failed to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA and find that the materials minimized the risks or overstated the efficacy of the product.  Plaintiff is seeking unspecified compensatory damages on behalf of herself and all persons and entities that purchased or otherwise acquired the Company’s securities between May 8, 2018, and June 20, 2019. Defendants dispute the Plaintiff’s claims and intend to defend the matter vigorously.  The Company is unable to determine any potential liability or financial exposure which may be associated with this matter at this time.